Effect of Erlotinib Plus Bevacizumab vs Erlotinib Alone on Progression-Free Survival in Patients With Advanced EGFR-Mutant Non–Small Cell Lung Cancer: A Phase 2 Randomized Clinical Trial

IMPORTANCE: Erlotinib is a standard first-line therapy for patients with epidermal growth factor receptor (EGFR)–mutant non–small cell lung cancer (NSCLC). Median progression-free survival (PFS) with erlotinib is approximately 10 months. OBJECTIVE: To determine whether adding bevacizumab to erlotini...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JAMA Oncol
Main Authors: Stinchcombe, Thomas E., Jänne, Pasi A., Wang, Xiaofei, Bertino, Erin M., Weiss, Jared, Bazhenova, Lyudmila, Gu, Lin, Lau, Christie, Paweletz, Cloud, Jaslowski, Anthony, Gerstner, Gregory J., Baggstrom, Maria Q., Graziano, Stephen, Bearden, James, Vokes, Everett E.
Formato: Artigo
Idioma:Inglês
Publicado em: American Medical Association 2019
Assuntos:
Original Investigation
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6692685/
https://ncbi.nlm.nih.gov/pubmed/31393548
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2019.1847
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados